Creating “future proof” antibodies vs. virus variants like Omicron with Ian Chan, co-founder of Abpro

Today's guest is Ian Chan the co-founder and executive chairman of Abpro. Abpro is improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Ian explains how their technology is "future proofing" antibodies. Recently, Abpro announced its ABP 310 COVID antibody retains neutralization activity against the SARS-CoV-2 Omicron variant, which is exciting. You’ll hear the full story coming up but first some quick takeaways you’ll get from today’s conversation:How Abpro is cutting the time to generate antibodies for testing from 1 year to 2 months. What all founders should focus on to facilitate fundraising - what Ian calls “first-class science”Unique challenges a company faces when it’s in high-growth mode and how to prepare. More about Ian he co-founded Abpro with his brother, Dr. Eugene Chan, who is the CEO. Not everyone goes into business with family but they’ve done it successfully a few times actually. Ian received an AB from Brown University and MBA from Harvard University. Show notes:https://abpro.com/Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron VariantQualioApply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldezQualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez